InvestLog
ACHV Achieve Life Sciences, Inc. logo

ACHV Achieve Life Sciences, Inc.

Healthcare
$4.69+1.96%ClosedMarket Cap: $250.5M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

23.45

P/S

0.00

EV/EBITDA

-4.62

DCF Value

$0.12

FCF Yield

-18.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-193.5%

ROA

-157.0%

ROIC

-195.0%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-10.2M$—
Q4 null$0.00$-14.7M$—
FY null$0.00$-54.6M$—
Q3 null$0.00$-14.4M$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$13.00

Target (Median)

$13.00

Target Range

$13.00 - $13.00

2 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell
HC Wainwright & Co.Buy
2026-04-16

Trading Activity

Insider Trades

View All
Martin Christopher Nathandirector
SellWed May 13
Martin Christopher Nathandirector
SellWed May 13
Royston Aarondirector
SellMon Apr 27
TPG GP A, LLC10 percent owner
SellFri Apr 24
TPG GP A, LLC10 percent owner
SellFri Apr 24

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

CA

Exchange

—

Beta

2.25

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

Peers

ALLO logoALLOARCT logoARCTAVIR logoAVIRCAPR logoCAPRHUMA logoHUMAIMRX logoIMRXSGMT logoSGMTTRDA logoTRDAVNDA logoVNDAVYGR logoVYGR